- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01706796
A Study Comparing PF-06273340 Immediate Release Tablet, PF-06273340 Modified Release Tablets To PF-06273340 Oral Solution In The Fasted State. This Study Will Also Compare PF-06273340 Modified Release Tablets In Fasted And Fed State
23 gennaio 2013 aggiornato da: Pfizer
A Phase 1, Open Label, Randomized, Single Dose, 5 Period Crossover Relative Bioavailability Study In Healthy Volunteers Evaluating Spray Dried Dispersion (SDD) Immediate Release (IR) PF-06273340 Tablet, Two SDD Modified Release (MR) Matrix Tablets In Comparison With PF-06273340 Oral Solution, Including Preliminary Assessment Of Food Effect
The primary purpose of this study is to estimate the relative bioavailability and food effect of PF-06273340 tablets.
Panoramica dello studio
Stato
Completato
Condizioni
Intervento / Trattamento
Tipo di studio
Interventistico
Iscrizione (Effettivo)
12
Fase
- Fase 1
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
-
Singapore, Singapore, 188770
- Pfizer Investigational Site
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
Da 21 anni a 55 anni (Adulto)
Accetta volontari sani
Sì
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion Criteria:
- Healthy male and/or female subjects of non-child bearing potential, between the ages of 21 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
- An informed consent document signed and dated by the subject.
- Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- Any condition possibly affecting drug absorption (eg, gastrectomy).
- A positive urine drug screen.
- History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of Screening.
- Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day.
- Treatment with an investigational drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first dose of study medication.
- Screening supine blood pressure >=140 mm Hg (systolic) or >=90 mm Hg (diastolic), on a single measurement (confirmed by a single repeat, if necessary) following at least 5 minutes of rest.
- Evidence or history of orthostatic hypotension.
- 12-lead ECG demonstrating QTc >450 or a QRS interval >120 msec at Screening. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated two more times and the average of the three QTc values should be used to determine the subject's eligibility.
- Pregnant or nursing females; females of childbearing potential, including those with tubal ligation.
- Use of prescription or nonprescription drugs, vitamins and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. Herbal supplements must be discontinued 28 days prior to the first dose of study medication. As an exception, acetaminophen/paracetamol may be used at doses of <=1 g/day. Limited use of non-prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case-by-case basis following approval by the sponsor.
- Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 56 days prior to dosing.
- History of sensitivity to heparin or heparin-induced thrombocytopenia.
- Unwilling or unable to comply with the Lifestyle guidelines described in this protocol.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
- Subjects who are investigational site staff members or relatives of those site staff members or subjects who are Pfizer employees directly involved in the conduct of the trial.
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: PF-06273340 Oral Solution Fasted
|
Oral solution, single dose, fasted
Immediate Release Tablet, single dose, fasted
Modified Release Tablet (short duration, MR1), single dose, fasted
Modified Release Tablet (long duration, MR2), single dose, fasted
Modified Release Tablet (short duration, MR1), single dose, fed
Modified Release Tablet (long duration, MR2), single dose, fed
|
Sperimentale: PF-06273340 Immediate Release Tablet Fasted
|
Oral solution, single dose, fasted
Immediate Release Tablet, single dose, fasted
Modified Release Tablet (short duration, MR1), single dose, fasted
Modified Release Tablet (long duration, MR2), single dose, fasted
Modified Release Tablet (short duration, MR1), single dose, fed
Modified Release Tablet (long duration, MR2), single dose, fed
|
Sperimentale: PF-06273340 Modified Release (MR1) Tablet Fasted
|
Oral solution, single dose, fasted
Immediate Release Tablet, single dose, fasted
Modified Release Tablet (short duration, MR1), single dose, fasted
Modified Release Tablet (long duration, MR2), single dose, fasted
Modified Release Tablet (short duration, MR1), single dose, fed
Modified Release Tablet (long duration, MR2), single dose, fed
|
Sperimentale: PF-06273340 Modified Release (MR2) Tablet Fasted
|
Oral solution, single dose, fasted
Immediate Release Tablet, single dose, fasted
Modified Release Tablet (short duration, MR1), single dose, fasted
Modified Release Tablet (long duration, MR2), single dose, fasted
Modified Release Tablet (short duration, MR1), single dose, fed
Modified Release Tablet (long duration, MR2), single dose, fed
|
Sperimentale: PF-06273340 Modified Release (MR1) Tablet Fed
|
Oral solution, single dose, fasted
Immediate Release Tablet, single dose, fasted
Modified Release Tablet (short duration, MR1), single dose, fasted
Modified Release Tablet (long duration, MR2), single dose, fasted
Modified Release Tablet (short duration, MR1), single dose, fed
Modified Release Tablet (long duration, MR2), single dose, fed
|
Sperimentale: PF-06273340 Modified Release (MR2) Tablet Fed
|
Oral solution, single dose, fasted
Immediate Release Tablet, single dose, fasted
Modified Release Tablet (short duration, MR1), single dose, fasted
Modified Release Tablet (long duration, MR2), single dose, fasted
Modified Release Tablet (short duration, MR1), single dose, fed
Modified Release Tablet (long duration, MR2), single dose, fed
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Maximum Observed Plasma Concentration (Cmax)
Lasso di tempo: up to 48 h post dose
|
up to 48 h post dose
|
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Lasso di tempo: up to 48 h post dose
|
up to 48 h post dose
|
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]
Lasso di tempo: up to 48 h post dose
|
up to 48 h post dose
|
Elimination half life
Lasso di tempo: up to 48 h post dose
|
up to 48 h post dose
|
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Lasso di tempo: up to 48 h post dose
|
up to 48 h post dose
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Pubblicazioni e link utili
La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.
Collegamenti utili
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio
1 novembre 2012
Completamento primario (Effettivo)
1 gennaio 2013
Completamento dello studio (Effettivo)
1 gennaio 2013
Date di iscrizione allo studio
Primo inviato
11 ottobre 2012
Primo inviato che soddisfa i criteri di controllo qualità
11 ottobre 2012
Primo Inserito (Stima)
15 ottobre 2012
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
24 gennaio 2013
Ultimo aggiornamento inviato che soddisfa i criteri QC
23 gennaio 2013
Ultimo verificato
1 gennaio 2013
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- B5261003
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su PF-06273340
-
PfizerCompletato
-
University of FloridaCompletatoSintomi gastrointestinali | Frequenza delle feci | Tempo di transito gastrointestinaleStati Uniti
-
PfizerCompletato
-
PfizerCompletato
-
PfizerCompletato